Anti HPV E7 TCR (Kite)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti HPV E7 TCR (Kite)
Drug Alias NameE7-TCRHPV-16 E7 TCRanti-HPV016 E7 TCRE7 TCR gene therapyKITE-439
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionProtein E7 modulatorsGene transference
TargetsProtein E7
Therapy Area/IndicationsVulvar DiseasesSquamous Intraepithelial Lesions of the CervixNeoplasm Metastasis +[19] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesKite PharmaNational Cancer Institute
Inactive CompaniesGilead Sciences Inc
Active IndicationsVulvar DiseasesNeoplasm MetastasisPenile Neoplasms +[17] 
Inactive IndicationsSquamous Intraepithelial Lesions of the CervixNeoplasms, Squamous Cell

Other Information

ATC CodeN/A
Related LinksN/A